ArticleThe Journal of pathology2019
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 52 citations in OpenAlex.
- Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.Histology and histopathology · 2026Review
- Inverted Urothelial Papilloma in a Young Woman: A Case Report and Review of Diagnostic Advances.Cureus · 2025Article
- Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.Nature communications · 2023Article
- An overview of the role of telomeres and telomerase in pre‑neoplastic lesions (Review).Molecular and clinical oncology · 2023Review
- KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.Cancer research · 2023Article
- Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets.Bladder cancer (Amsterdam, Netherlands) · 2023Review
- Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder CarcinomaIranian biomedical journal · 2022Article
- Proteomic-Based Machine Learning Analysis Reveals PYGB as a Novel Immunohistochemical Biomarker to Distinguish Inverted Urothelial Papilloma From Low-Grade Papillary Urothelial Carcinoma With Inverted Growth.Frontiers in oncology · 2022Article
- Article
- Molecular Pathology of Urothelial Carcinoma.Surgical pathology clinics · 2021Review
- Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern.Journal of pathology and translational medicine · 2021Review
- [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].Der Pathologe · 2021Review
- A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?Translational andrology and urology · 2021Review
- Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis.Clinics and practice · 2021Review
- Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations.Diagnostic pathology · 2020Article
- Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities.The Journal of pathology · 2020Article
- Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck.The journal of pathology. Clinical research · 2020Article
- Article
- PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.Cancers · 2019Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
Inverted urothelial papilloma (IUP) and urothelial papilloma (UP) are rare urothelial neoplasms that typically follow a benign clinical course. Oncogenic mutations in FGFR3, HRAS, and the TERT promoter have been reported in these entities but no comprehensive molecular analysis has been performed. We sought to characterize the genomic landscape of IUP and UP using whole-exome and targeted next-generation sequencing. In IUP, 10 of 11 tumors harbored oncogenic hotspot mutations in HRAS and the remaining tumor had an oncogenic KRAS mutation. None of the IUP tumors harbored TERT promoter or FGFR3 mutations. In UP, 8 of 11 tumors had oncogenic KRAS mutations and two had oncogenic HRAS mutations. One UP tumor had oncogenic mutations in FGFR3, PIK3CA, and the TERT promoter, and arose in a patient with recurrent non-invasive papillary urothelial carcinomas. In contrast to urothelial carcinoma, the APOBEC mutational signature was not present in any IUP and UP tumors, and oncogenic alterations in chromatin remodeling genes were uncommon in both IUP and UP. The current study suggests that IUP and UP are driven primarily by RAS pathway activation and lack the more common genomic features of urothelial cancers. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.